Covid-19 vaccine (LH Indholdsside)

<Provider Id="sundheddkcms">
  <Item Id="{D2ACFD42-4527-429A-9ECF-40C3F889542A}" Name="Covid-19-vaccine" Type="LHContentPage" ParentProviderId="sundheddkcms" ParentItemId="{FAF84268-6916-46D2-AB3D-561BDBE5CEF6}" SortOrder="500" PublishDate="2021-01-12T15:32:00" DeleteDate="2999-12-31T00:00:00" PotItemType="">
    <Content>
      <HtmlField Name="PageContent"><![CDATA[<h2>Anvendelse</h2>
<ul>
    <li>Forebyggende mod&nbsp;<a href="~/link.aspx?_id=BC30592074074A1D94C3B04612A86576&amp;_z=z">infektion med SARS-CoV-2</a></li>
</ul>
<h2>Indikationer</h2>
<ul>
    <li>Prim&aelig;r forebyggelse mod infektion med SARS-CoV-2</li>
</ul>
<h2>Vacciner</h2>
<ul>
    <li>For s&aelig;sonen 2025-2026 tilbydes udelukkende den variantopdaterede covid-19-vaccine Cominarty LP.8.1 i det gratis vaccinationsprogram for risikogrupper</li>
    <li>F&oslash;lgende vacciner er godkendt til brug i Danmark:
    <ul>
        <li>[DliActiveSubstance;9649;Comirnaty&reg;] er udviklet af det tyske firma BioNTech i samarbejde med det amerikanske firma Pfizer</li>
        <li><a rel="noopener noreferrer" href="https://pro.medicin.dk/Medicin/Praeparater/9965" target="_blank">Nuvaxovid</a>&nbsp;er udviklet af amerikanske Novavax</li>
        <li>Udg&aring;et 1/9-25:&nbsp;[DliActiveSubstance;9661;Spikevax&reg;]&nbsp;er udviklet af det amerikanske firma Moderna (tidligere kaldtes vaccinen ogs&aring; Moderna)</li>
    </ul>
    </li>
</ul>
<h2>Om vaccinerne</h2>
<ul>
    <li>[DliActiveSubstance;9649;Comirnaty&reg;] og&nbsp;[DliActiveSubstance;9661;Spikevax&reg;]: Vaccinerne er baseret p&aring; RNA-teknologi, som ikke tidligere har v&aelig;ret anvendt i vaccinesammenh&aelig;ng. Den aktive komponent er hverken hel virus eller bestanddele af virus, men derimod specifikt mRNA, der koder for virus' overfladeprotein (spike-protein). Efter injektion i en muskel, vil mRNA'et i muskelcellerne omskrives (translateres) til protein, der eksporteres og pr&aelig;senteres for immunsystemet af antigenpr&aelig;senterende celler. Specifikke antistoffer mod virus' overfladeprotein vil dern&aelig;st syntetiseres af B-lymfocytter, og T-lymfocytter vil sikre immunologisk hukommelse. Det injicerede mRNA nedbrydes umiddelbart efter omskrivning til protein</li>
    <li>Novaxovid er en adjuveret vaccine - kun godkendt til prim&aelig;rvaccination
    <ul>
        <li>Novaxovid best&aring;r af oprenset rekombinant fuldl&aelig;ngde-SARS-CoV-2-spike-protein (S). Tils&aelig;tningen af adjuvans fremmer aktivering af cellerne i det innate immunsystem, hvorved omfanget af det S-protein-specifikke immunrespons &oslash;ges. De to vaccinekomponenter fremkalder immunrespons via B- og T-cellers respons p&aring; S-proteinet<a href="https://www.ema.europa.eu/en/medicines/human/EPAR/nuvaxovid" data-type="other-reference" data-value="EMA: Novaxovid" data-url="https://www.ema.europa.eu/en/medicines/human/EPAR/nuvaxovid" title="EMA: Novaxovid"><sup>1</sup></a></li>
    </ul>
    </li>
    <li>I store randomiserede fors&oslash;g demonstrerer b&aring;de mRNA vacciner (Corminaty og Spikevax) og Novaxovid 96 - 100 procents beskyttelse mod alvorlig infektion. Dog var incidencen af alvorlige infektioner i studierne meget lave<a href=" " data-type="journal-reference" data-value="Thomas SJ, Moreira ED Jr, Kitchin N, Absalon J, Gurtman A, Lockhart S, Perez JL, Pérez Marc G, Polack FP, Zerbini C, Bailey R, Swanson KA, Xu X, Roychoudhury S, Koury K, Bouguermouh S, Kalina WV, Cooper D, Frenck RW Jr, Hammitt LL, Türeci Ö, Nell H, Schaefer A, Ünal S, Yang Q, Liberator P, Tresnan DB, Mather S, Dormitzer PR, Şahin U, Gruber WC, Jansen KU, C4591001 Clinical Trial Group, Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6 Months. N Engl J Med 2021;385: 1761-1773" data-value-piped="Thomas SJ, Moreira ED Jr, Kitchin N, Absalon J, Gurtman A, Lockhart S, Perez JL, Pérez Marc G, Polack FP, Zerbini C, Bailey R, Swanson KA, Xu X, Roychoudhury S, Koury K, Bouguermouh S, Kalina WV, Cooper D, Frenck RW Jr, Hammitt LL, Türeci Ö, Nell H, Schaefer A, Ünal S, Yang Q, Liberator P, Tresnan DB, Mather S, Dormitzer PR, Şahin U, Gruber WC, Jansen KU, C4591001 Clinical Trial Group|Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6 Months.|N Engl J Med|2021|385|1761-1773|34525277" data-url="reference-link" data-pubmedid="34525277" title="Thomas SJ, Moreira ED Jr, Kitchin N, Absalon J, Gurtman A, Lockhart S, Perez JL, Pérez Marc G, Polack FP, Zerbini C, Bailey R, Swanson KA, Xu X, Roychoudhury S, Koury K, Bouguermouh S, Kalina WV, Cooper D, Frenck RW Jr, Hammitt LL, Türeci Ö, Nell H, Schaefer A, Ünal S, Yang Q, Liberator P, Tresnan DB, Mather S, Dormitzer PR, Şahin U, Gruber WC, Jansen KU, C4591001 Clinical Trial Group, Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6 Months. N Engl J Med 2021;385: 1761-1773"><sup>2</sup></a>,<a href=" " data-type="journal-reference" data-value="Dunkle LM, Kotloff KL, Gay CL, Áñez G, Adelglass JM, Barrat Hernández AQ, Harper WL, Duncanson DM, McArthur MA, Florescu DF, McClelland RS, Garcia-Fragoso V, Riesenberg RA, Musante DB, Fried DL, Safirstein BE, McKenzie M, Jeanfreau RJ, Kingsley JK, Henderson JA, Lane DC, Ruíz-Palacios GM, Corey L, Neuzil KM, Coombs RW, Greninger AL, Hutter J, Ake JA, Smith K, Woo W, Cho I, Glenn GM, Dubovsky F, 2019nCoV-301 Study Group, Efficacy and Safety of NVX-CoV2373 in Adults in the United States and Mexico. N Engl J Med 2022;386: 531-543" data-value-piped="Dunkle LM, Kotloff KL, Gay CL, Áñez G, Adelglass JM, Barrat Hernández AQ, Harper WL, Duncanson DM, McArthur MA, Florescu DF, McClelland RS, Garcia-Fragoso V, Riesenberg RA, Musante DB, Fried DL, Safirstein BE, McKenzie M, Jeanfreau RJ, Kingsley JK, Henderson JA, Lane DC, Ruíz-Palacios GM, Corey L, Neuzil KM, Coombs RW, Greninger AL, Hutter J, Ake JA, Smith K, Woo W, Cho I, Glenn GM, Dubovsky F, 2019nCoV-301 Study Group|Efficacy and Safety of NVX-CoV2373 in Adults in the United States and Mexico.|N Engl J Med|2022|386|531-543|34910859" data-url="reference-link" data-pubmedid="34910859" title="Dunkle LM, Kotloff KL, Gay CL, Áñez G, Adelglass JM, Barrat Hernández AQ, Harper WL, Duncanson DM, McArthur MA, Florescu DF, McClelland RS, Garcia-Fragoso V, Riesenberg RA, Musante DB, Fried DL, Safirstein BE, McKenzie M, Jeanfreau RJ, Kingsley JK, Henderson JA, Lane DC, Ruíz-Palacios GM, Corey L, Neuzil KM, Coombs RW, Greninger AL, Hutter J, Ake JA, Smith K, Woo W, Cho I, Glenn GM, Dubovsky F, 2019nCoV-301 Study Group, Efficacy and Safety of NVX-CoV2373 in Adults in the United States and Mexico. N Engl J Med 2022;386: 531-543"><sup>3</sup></a>,<a href=" " data-type="journal-reference" data-value="El Sahly HM, Baden LR, Essink B, Doblecki-Lewis S, Martin JM, Anderson EJ, Campbell TB, Clark J, Jackson LA, Fichtenbaum CJ, Zervos M, Rankin B, Eder F, Feldman G, Kennelly C, Han-Conrad L, Levin M, Neuzil KM, Corey L, Gilbert P, Janes H, Follmann D, Marovich M, Polakowski L, Mascola JR, Ledgerwood JE, Graham BS, August A, Clouting H, Deng W, Han S, Leav B, Manzo D, Pajon R, Schödel F, Tomassini JE, Zhou H, Miller J, COVE Study Group, Efficacy of the mRNA-1273 SARS-CoV-2 Vaccine at Completion of Blinded Phase. N Engl J Med 2021;385: 1774-1785" data-value-piped="El Sahly HM, Baden LR, Essink B, Doblecki-Lewis S, Martin JM, Anderson EJ, Campbell TB, Clark J, Jackson LA, Fichtenbaum CJ, Zervos M, Rankin B, Eder F, Feldman G, Kennelly C, Han-Conrad L, Levin M, Neuzil KM, Corey L, Gilbert P, Janes H, Follmann D, Marovich M, Polakowski L, Mascola JR, Ledgerwood JE, Graham BS, August A, Clouting H, Deng W, Han S, Leav B, Manzo D, Pajon R, Schödel F, Tomassini JE, Zhou H, Miller J, COVE Study Group|Efficacy of the mRNA-1273 SARS-CoV-2 Vaccine at Completion of Blinded Phase.|N Engl J Med|2021|385|1774-1785|34551225" data-url="reference-link" data-pubmedid="34551225" title="El Sahly HM, Baden LR, Essink B, Doblecki-Lewis S, Martin JM, Anderson EJ, Campbell TB, Clark J, Jackson LA, Fichtenbaum CJ, Zervos M, Rankin B, Eder F, Feldman G, Kennelly C, Han-Conrad L, Levin M, Neuzil KM, Corey L, Gilbert P, Janes H, Follmann D, Marovich M, Polakowski L, Mascola JR, Ledgerwood JE, Graham BS, August A, Clouting H, Deng W, Han S, Leav B, Manzo D, Pajon R, Schödel F, Tomassini JE, Zhou H, Miller J, COVE Study Group, Efficacy of the mRNA-1273 SARS-CoV-2 Vaccine at Completion of Blinded Phase. N Engl J Med 2021;385: 1774-1785"><sup>4</sup></a>,<a href="https://www.cdc.gov/mmwr/volumes/72/wr/mm7224a6.htm" data-type="other-reference" data-value="CDC: Comparison of COVID-19 Mortality Rates Among Adults Aged ≥65 Years Who Were Unvaccinated and Those Who Received a Bivalent Booster Dose Within the Preceding 6 Months — 20 U.S. Jurisdictions, September 18, 2022–April 1, 2023" data-url="https://www.cdc.gov/mmwr/volumes/72/wr/mm7224a6.htm" title="CDC: Comparison of COVID-19 Mortality Rates Among Adults Aged ≥65 Years Who Were Unvaccinated and Those Who Received a Bivalent Booster Dose Within the Preceding 6 Months — 20 U.S. Jurisdictions, September 18, 2022–April 1, 2023"><sup>5</sup></a>,&nbsp;<a href="https://www.who.int/news-room/feature-stories/detail/the-valneva-vla2001-covid-19-vaccine--what-you-need-to-know" data-type="other-reference" data-value="WHO: The Valneva VLA2001 COVID-19 vaccine: What you need to know" data-url="https://www.who.int/news-room/feature-stories/detail/the-valneva-vla2001-covid-19-vaccine--what-you-need-to-know" title="WHO: The Valneva VLA2001 COVID-19 vaccine: What you need to know"><sup>6</sup></a>&nbsp;og data, der demonstrerer at vaccinerne beskytter mod alvorlig sygdom fra store observationelle studier<a href=" " data-type="journal-reference" data-value="Haas EJ, Angulo FJ, McLaughlin JM, Anis E, Singer SR, Khan F, Brooks N, Smaja M, Mircus G, Pan K, Southern J, Swerdlow DL, Jodar L, Levy Y, Alroy-Preis S, Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data. Lancet 2021;397: 1819-1829" data-value-piped="Haas EJ, Angulo FJ, McLaughlin JM, Anis E, Singer SR, Khan F, Brooks N, Smaja M, Mircus G, Pan K, Southern J, Swerdlow DL, Jodar L, Levy Y, Alroy-Preis S|Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data.|Lancet|2021|397|1819-1829|33964222" data-url="reference-link" data-pubmedid="33964222" title="Haas EJ, Angulo FJ, McLaughlin JM, Anis E, Singer SR, Khan F, Brooks N, Smaja M, Mircus G, Pan K, Southern J, Swerdlow DL, Jodar L, Levy Y, Alroy-Preis S, Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data. Lancet 2021;397: 1819-1829"><sup>7</sup></a>,<a href=" " data-type="journal-reference" data-value="Vasileiou E, Simpson CR, Shi T, Kerr S, Agrawal U, Akbari A, Bedston S, Beggs J, Bradley D, Chuter A, de Lusignan S, Docherty AB, Ford D, Hobbs FR, Joy M, Katikireddi SV, Marple J, McCowan C, McGagh D, McMenamin J, Moore E, Murray JL, Pan J, Ritchie L, Shah SA, Stock S, Torabi F, Tsang RS, Wood R, Woolhouse M, Robertson C, Sheikh A, Interim findings from first-dose mass COVID-19 vaccination roll-out and COVID-19 hospital admissions in Scotland: a national prospective cohort study. Lancet 2021;397: 1646-1657" data-value-piped="Vasileiou E, Simpson CR, Shi T, Kerr S, Agrawal U, Akbari A, Bedston S, Beggs J, Bradley D, Chuter A, de Lusignan S, Docherty AB, Ford D, Hobbs FR, Joy M, Katikireddi SV, Marple J, McCowan C, McGagh D, McMenamin J, Moore E, Murray JL, Pan J, Ritchie L, Shah SA, Stock S, Torabi F, Tsang RS, Wood R, Woolhouse M, Robertson C, Sheikh A|Interim findings from first-dose mass COVID-19 vaccination roll-out and COVID-19 hospital admissions in Scotland: a national prospective cohort study.|Lancet|2021|397|1646-1657|33901420" data-url="reference-link" data-pubmedid="33901420" title="Vasileiou E, Simpson CR, Shi T, Kerr S, Agrawal U, Akbari A, Bedston S, Beggs J, Bradley D, Chuter A, de Lusignan S, Docherty AB, Ford D, Hobbs FR, Joy M, Katikireddi SV, Marple J, McCowan C, McGagh D, McMenamin J, Moore E, Murray JL, Pan J, Ritchie L, Shah SA, Stock S, Torabi F, Tsang RS, Wood R, Woolhouse M, Robertson C, Sheikh A, Interim findings from first-dose mass COVID-19 vaccination roll-out and COVID-19 hospital admissions in Scotland: a national prospective cohort study. Lancet 2021;397: 1646-1657"><sup>8</sup></a>,<a href=" " data-type="journal-reference" data-value="McNamara LA, Wiegand RE, Burke RM, Sharma AJ, Sheppard M, Adjemian J, Ahmad FB, Anderson RN, Barbour KE, Binder AM, Dasgupta S, Dee DL, Jones ES, Kriss JL, Lyons BC, McMorrow M, Payne DC, Reses HE, Rodgers LE, Walker D, Verani JR, Schrag SJ, Estimating the early impact of the US COVID-19 vaccination programme on COVID-19 cases, emergency department visits, hospital admissions, and deaths among adults aged 65 years and older: an ecological analysis of national surveillance data. Lancet 2022;399: 152-160" data-value-piped="McNamara LA, Wiegand RE, Burke RM, Sharma AJ, Sheppard M, Adjemian J, Ahmad FB, Anderson RN, Barbour KE, Binder AM, Dasgupta S, Dee DL, Jones ES, Kriss JL, Lyons BC, McMorrow M, Payne DC, Reses HE, Rodgers LE, Walker D, Verani JR, Schrag SJ|Estimating the early impact of the US COVID-19 vaccination programme on COVID-19 cases, emergency department visits, hospital admissions, and deaths among adults aged 65 years and older: an ecological analysis of national surveillance data.|Lancet|2022|399|152-160|34741818" data-url="reference-link" data-pubmedid="34741818" title="McNamara LA, Wiegand RE, Burke RM, Sharma AJ, Sheppard M, Adjemian J, Ahmad FB, Anderson RN, Barbour KE, Binder AM, Dasgupta S, Dee DL, Jones ES, Kriss JL, Lyons BC, McMorrow M, Payne DC, Reses HE, Rodgers LE, Walker D, Verani JR, Schrag SJ, Estimating the early impact of the US COVID-19 vaccination programme on COVID-19 cases, emergency department visits, hospital admissions, and deaths among adults aged 65 years and older: an ecological analysis of national surveillance data. Lancet 2022;399: 152-160"><sup>9</sup></a></li>
    <li>Vaccinernes effektivitet aftager over m&aring;neder, og beskyttelsesgraden mod forskellige virusvarianter er ringere end overfor det oprindelige SARS-CoV-2. Revaccination af s&aelig;rlige risikogrupper med variantopdaterede vacciner er derfor l&oslash;bende n&oslash;dvendigt</li>
</ul>
<h2>Dosering<a href="https://paediatri.dk/images/dokumenter/retningslinjer_2024/coronavaccination_af_b%C3%B8rn.pdf" data-type="other-reference" data-value="Dansk Pædiatrisk Selskab: Vaccination af børn og unge i øget risiko ved COVID-19 (2024)
" data-url="https://paediatri.dk/images/dokumenter/retningslinjer_2024/coronavaccination_af_b%C3%B8rn.pdf" title="Dansk Pædiatrisk Selskab: Vaccination af børn og unge i øget risiko ved COVID-19 (2024)
"><sup>#</sup></a>,<a href="https://pro.medicin.dk/Medicin/Praeparater/10804" data-type="other-reference" data-value="Promedicin.dk: Comirnaty® JN.1" data-url="https://pro.medicin.dk/Medicin/Praeparater/10804" title="Promedicin.dk: Comirnaty® JN.1"><sup>#</sup></a>,<a href="https://www.ssi.dk/vaccinationer/covid-19-vaccination/sp-og-svar" data-type="other-reference" data-value="Statens Serum Institut: Spørgsmål og svar om covid-19 vaccination (2024)" data-url="https://www.ssi.dk/vaccinationer/covid-19-vaccination/sp-og-svar" title="Statens Serum Institut: Spørgsmål og svar om covid-19 vaccination (2024)"><sup>#</sup></a></h2>
<ul>
    <li>I vaccinationsprogrammet 2025/26 gives &eacute;n dosis uanset tidligere vaccination. Vaccinen skal dog gives mindst 3 mdr. efter seneste COVID19-vaccination</li>
    <li>B&oslash;rn er ikke i m&aring;lgruppen for covid-19 vaccination i s&aelig;sonen 2025/26. B&oslash;rn og unge i s&aelig;rlig &oslash;get risiko for et alvorligt forl&oslash;b kan tilbydes vaccination efter individuel vurdering af speciall&aelig;ge i p&aelig;diatri.&nbsp;B&oslash;rn, der skal vaccineres, kan vaccineres med Comirnaty LP 8.1</li>
    <li>Voksne og b&oslash;rn fra 5 &aring;r skal kun modtage 1 vaccine uanset tidligere vaccinationsstatus</li>
    <li>Voksne og b&oslash;rn/unge &ge; 12 &aring;r (vaccine med gr&aring;t l&aring;g)
    <ul>
        <li>30 mikrogram (0,3 ml) i.m.</li>
    </ul>
    </li>
    <li>B&oslash;rn 5-11 &aring;r (vaccine med bl&aring;t l&aring;g)
    <ul>
        <li>10 mikrogram (0,3 ml) i.m.</li>
    </ul>
    </li>
    <li>B&oslash;rn 6 mdr. - 4 &aring;r (vaccine med gult l&aring;g)</li>
    <li>B&oslash;rn fra 6 m&aring;neder til 4 &aring;r uden tidligere gennemf&oslash;relse af et COVID-19 prim&aelig;rt forl&oslash;b eller tidligere SARS-CoV-2-infektion skal modtage 3 vaccinationer
    <ul>
        <li>1. dosis p&aring; 3 mikrogram (0,3 ml) i.m. (efter fortynding). 2. dosis gives 21 dage efter 1. dosis, og 3. dosis skal gives mindst 8 uger efter 2. dosis</li>
    </ul>
    </li>
    <li>Hvis et barn fylder 5 &aring;r mellem doserne i deres vaccinationsforl&oslash;b, skal serien gennemf&oslash;res med det samme dosisniveau p&aring; 3 mikrogram</li>
</ul>
<h3>S&aelig;sonvaccination af risikogrupper</h3>
<ul>
    <li>Fra 1/10-25 til 20/12-25 tilbydes vaccination med variantopdaterede vacciner til personer
    <ul>
        <li>Alle p&aring; 65 &aring;r og derover</li>
        <li>Personer under 65 &aring;r, der er i &oslash;get risiko for et alvorligt forl&oslash;b fx.
        <ul>
            <li>Personer med kroniske lungesygdomme</li>
            <li>Personer med hjerte- og karsygdomme (undtaget isoleret, velreguleret forh&oslash;jet blodtryk)</li>
            <li>Personer med diabetes 1 eller 2</li>
            <li>Personer med medf&oslash;dt eller erhvervet immundefekt - fx personer med immunglobulindefekter, organ- eller stamcelletransplantation, kr&aelig;ft i behandling med kemoterapi eller personer i anden immund&aelig;mpende behandling</li>
            <li>Personer med p&aring;virket respiration p&aring; grund af nedsat muskelkraft</li>
            <li>Personer med kronisk lever- eller nyresygdom</li>
            <li>Personer med andre kroniske sygdomme, hvor tilstanden medf&oslash;rer, at covid-19 udg&oslash;r en alvorlig sundhedsrisiko&nbsp;fx personer med alvorlig reumatologisk sygdom, alvorlig neurologisk sygdom, korttarmssyndrom</li>
            <li>Personer med sv&aelig;r overv&aelig;gt (BMI over 35)</li>
            <li>Personer med andre alvorlige sygdomme, hvor tilstanden medf&oslash;rer, at covid-19 udg&oslash;r en alvorlig sundhedsrisiko,&nbsp;fx personer med sv&aelig;r psykisk lidelse, Downs syndrom eller sv&aelig;rt misbrug.</li>
            <li>Personer i samme husstand som personer med medf&oslash;dt eller erhvervet immundefekt eller b&oslash;rn i &oslash;get risiko for alvorlig covid-19 </li>
        </ul>
        </li>
    </ul>
    </li>
    <li>Vaccination af b&oslash;rn under 18 &aring;r med kronisk sygdom efter l&aelig;gelig vurdering af speciall&aelig;ge i p&aelig;diatri. Kun f&aring; b&oslash;rn har behov for s&aelig;sonvaccination mod covid-19. Det er&nbsp; kun&nbsp; b&oslash;rn i &oslash;get risiko for et alvorligt forl&oslash;b af COVID-19, der tilbydes vaccination mod SARS-CoV-2. Definitionen af risikob&oslash;rn er udarbejdet af Dansk P&aelig;diatrisk Selskab og er forskellig fra definitionen over b&oslash;rn i &oslash;get risiko for influenza.</li>
</ul>
<h2>Kontraindikationer</h2>
<ul>
    <li>Allergi overfor indholdsstoffer</li>
    <li>Allergisk reaktion efter f&oslash;rste dosis vaccine - ved tidligere anafylaksi grundet vaccinen skal det vurderes af l&aelig;ge, om der m&aring; vaccineres</li>
    <li>Personer, som tidligere har oplevet anafylaktisk straksreaktion efter vaccination eller efter injektion af et l&aelig;gemiddel, b&oslash;r vurderes af l&aelig;ge, f&oslash;r de vaccineres med Cominnaty LP.8.1, da de er i &oslash;get risiko for en allergisk reaktion</li>
</ul>
<h4>Udskydelse af vaccination ved&nbsp;</h4>
<ul>
    <li>Sygdom med feber &gt; 38,0 ⁰C</li>
    <li>Akut infektion</li>
</ul>
<h4>Trombocytopeni og koagulationsforstyrrelser&nbsp;</h4>
<ul>
    <li>Forsigtighed, da bl&oslash;dning og h&aelig;matom generelt ses efter i.m. injektion.</li>
</ul>
<h2>Andre allergier</h2>
<ul>
    <li>Personer, der er allergiske over for f&oslash;devarer (inklusiv &aelig;g, n&oslash;dder, skaldyr og jordn&oslash;dder) eller pollen, kan som udgangspunkt godt blive vaccineret, da ingen af de godkendte vacciner er produceret p&aring; &aelig;g eller indeholder rester af n&oslash;dder, jordn&oslash;dder, skaldyr eller pollen</li>
</ul>
<h2>Bivirkninger/komplikationer</h2>
<ul>
    <li>&Oslash;mhed p&aring; injektionssted</li>
    <li>Tr&aelig;thed, hovedpine, muskel- og ledsmerter, kulderystelser, let til moderat feber samt r&oslash;dme og h&aelig;velse p&aring; indstiksstedet er almindelige</li>
</ul>
<h2>Patientinformation</h2>
<ul>
    <li>Sundhedsstyrelsen:<a rel="noopener noreferrer" href="https://www.sst.dk/da/corona" target="_blank"> Covid-19 og influenza</a></li>
    <li><a href="~/link.aspx?_id=4EF792408EC74724AD6522ED9C175255&amp;_z=z">COVID-19 vaccine- for borgere</a></li>
    <li><a href="~/link.aspx?_id=7DD3D3E4751143709E099589AA2380CE&amp;_z=z">COVID-19, coronavirus</a></li>
    <li><a href="~/link.aspx?_id=1D32CFEF3ADF49D786CBE36F9F64CAE3&amp;_z=z">COVID-19 hos b&oslash;rn - for borgere</a></li>
</ul>
<h2>Andre sundhedsfaglige artikler</h2>
<ul>
    <li>Promedicin:&nbsp;<a href="https://pro.medicin.dk/Medicin/Praeparater/11135">Comirnaty&reg; LP.8.1 - information til sundhedsfaglige - Medicin.dk</a></li>
    <li>Retsinformation&nbsp;<a href="https://www.retsinformation.dk/eli/lta/2025/1111">Bekendtg&oslash;relse om gratis vaccination mod influenza og covid-19 til visse persongrupper</a></li>
    <li>Sundhedsstyrelsen: <a rel="noopener noreferrer" href="https://www.sst.dk/da/Vaccination" target="_blank">Vaccination mod influenza og covid-19</a></li>
    <li>Statens Serum Institut:&nbsp;<a rel="noopener noreferrer" href="https://www.ssi.dk/vaccinationer/covid-19-vaccination/sp-og-svar" target="_blank">Sp&oslash;rgsm&aring;l og svar om covid-19-vaccination</a></li>
    <li>Statens Serum Institut&nbsp;<a href="https://www.ssi.dk/vaccinationer/vaccineleksikon/c/covid-19-vaccine-pfizer-biontech-variantopdateret-comirnaty-lp81">Covid-19 vaccine Pfizer-Biontech Variantopdateret (Comirnaty LP.8.1)</a></li>
    <li>Dansk P&aelig;diatrisk Selskab:&nbsp;<a rel="noopener noreferrer" href="https://paediatri.dk/images/dokumenter/retningslinjer_2024/coronavaccination_af_b%C3%B8rn.pdf" target="_blank">Vaccination af b&oslash;rn og unge i &oslash;get risiko ved COVID-19</a></li>
</ul>]]></HtmlField>
      <LinkListField Name="Spot2">
        <LinkField linktype="internal">{99A85AFD-2F7A-4B5D-A1C9-C2701D5E7D30}</LinkField>
      </LinkListField>
      <TextField Name="DoctorsHandbookID">40512</TextField>
      <TextField Name="PageTitle">COVID-19 vaccine</TextField>
      <TextField Name="NavigationTitle">COVID-19 vaccine</TextField>
      <CheckBoxField Name="ShowInMenu">true</CheckBoxField>
      <CheckBoxField Name="ShowInContentField">true</CheckBoxField>
      <DateTimeField Name="RevisedDate">2024-10-03T10:17:00</DateTimeField>
      <LinkListField Name="Authors">
        <LinkField linktype="internal">{BF3B1396-E7F6-403B-9F8A-6E8A0F54B129}</LinkField>
        <LinkField linktype="internal">{ED7CEC94-3F7A-4FB5-BBB0-A3681BCFC481}</LinkField>
      </LinkListField>
      <LinkListField Name="Organization">
        <LinkField linktype="internal">{CF77E8B9-9937-42B2-85DF-76B0F4E401F0}</LinkField>
      </LinkListField>
      <LinkListField Name="SearchAreaID">
        <LinkField linktype="internal">3</LinkField>
      </LinkListField>
      <TextField Name="Description">Vacciner mod COVID-19 anvendes forebyggende mod infektion med SARS-CoV-2</TextField>
      <LinkListField Name="LHPHEditor">
        <LinkField linktype="internal">{C70DFB71-BE40-455A-BD6B-5AFF199797D9}</LinkField>
      </LinkListField>
      <TextField Name="__Updated by">sitecore\anda</TextField>
      <TextField Name="MetaKeywords">covid-19, coronavirus, coronavaccine, SARS CoV-2, coronavaccine, corona, vaccination mod COVID-19</TextField>
      <LinkListField Name="InformationCategory">
        <LinkField linktype="internal">IC_3</LinkField>
      </LinkListField>
      <LinkListField Name="InformationType">
        <LinkField linktype="internal">7</LinkField>
      </LinkListField>
      <LinkListField Name="SearchTargetGroup">
        <LinkField linktype="internal">2</LinkField>
      </LinkListField>
    </Content>
    <Medias />
  </Item>
</Provider>

25.093 characters